The week in pharma: action, reaction and insight – week to April 4
By Barbara Obstoj-Cardwell. Editor
In the news last week, US Center for Biologics Evaluation and Research (CBER) Dr Peter Marks quit his post after reported pressure from a Human Health Services (HHS) official. On the research front, Merck & Co presented positive Phase III data on its Winrevair in pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) meeting. Also, Swiss biotech AC Immune shared new Phase II data on its Parkinson’s disease candidate ACI-7104-056. Late last Wednesday, US President Donald Trump dropped a bombshell of tariffs of various amounts on countries around the world, although there was ambiguity as to how and when they would impact pharma and biotech products.
Concerning FDA resignation letter
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze